Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
DePuy International
ClinicalTrials.gov Identifier:
NCT00872547
First received: March 30, 2009
Last updated: September 1, 2011
Last verified: September 2011

March 30, 2009
September 1, 2011
September 2006
June 2015   (final data collection date for primary outcome measure)
Kaplan-Meier survivorship calculated at the five-year time-point [ Time Frame: 5yrs ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00872547 on ClinicalTrials.gov Archive Site
  • Annual Kaplan-Meier survivorship calculations [ Time Frame: Annually ] [ Designated as safety issue: Yes ]
  • Harris Hip Score [ Time Frame: 3mths, 1yr, 2yrs, 5yrs, 10yrs, and 15yrs post-surgery ] [ Designated as safety issue: No ]
  • Radiographic analysis [ Time Frame: 3mths, 1yr, 2yrs, 5yrs, 10yrs, and 15yrs post-surgery ] [ Designated as safety issue: No ]
  • Oxford Hip Score [ Time Frame: 3mths, 6mths and annually post-surgery ] [ Designated as safety issue: No ]
  • UCLA Activity Score [ Time Frame: 3mths, 6mths and annually post-surgery ] [ Designated as safety issue: No ]
  • Hip Outcome Score [ Time Frame: 3mths, 6mths and annually post-surgery ] [ Designated as safety issue: No ]
  • EuroQol EQ-5D [ Time Frame: 3mths, 6mths and annually post-surgery ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement
Prospective, International Multi-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of a Large Metal-on-Metal (MoM) Bearing Comprising a DePuy ASR™ Cup in Conjunction With Either a DePuy ASR™ Hip Resurfacing Femoral Component or a DePuy ASR™ XL Head in Subjects With Indications Suitable for Either a Primary Resurfacing Arthroplasty or Primary Total Hip Arthroplasty

The purpose of this study is to monitor the performance of a large metal-on-metal bearing from the DePuy ASR™ System in the treatment of patients with hip joint disease requiring hip resurfacing surgery or a total hip replacement. Patients who enter the study will be evaluated at regular intervals following hip surgery using patient, clinical and x-ray assessments.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Post-traumatic Arthritis
  • Collagen Disorders
  • Avascular Necrosis
  • Nonunion of Femoral Fractures
  • Congenital Hip Dysplasia
  • Slipped Capital Femoral Epiphysis
  • Device: DePuy ASR™ Hip System
    Resurfacing system
  • Device: DePuy ASR™ XL Head / ASR™ Acetabular Cup System
    Large Metal-on-Metal Total Hip Replacement
  • Active Comparator: 1
    Resurfacing system
    Intervention: Device: DePuy ASR™ Hip System
  • Active Comparator: 2
    Large Metal-on-Metal Total Hip Replacement
    Intervention: Device: DePuy ASR™ XL Head / ASR™ Acetabular Cup System
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
624
Not Provided
June 2015   (final data collection date for primary outcome measure)

General Inclusion Criteria:

i) Male or female subjects, aged between 18 and 65 years inclusive.

ii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.

iii) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.

Inclusion Criteria for DePuy ASR™ Resurfacing system:

i) Subjects with primary osteoarthritis indicated for standard MoM hip resurfacing arthroplasty with cementless fixation in the acetabulum.

Inclusion Criteria for ASR™ XL Head system:

i) Subjects whose bone morphology and bone quality mean that standard MoM hip resurfacing arthroplasty is not indicated, but for whom cementless fixation in the acetabulum and receipt of a large MoM bearing are still possible.

General Exclusion Criteria:

i) Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.

ii) Subjects with compromised renal function defined as those whose measured values lie outside the normal range for a particular investigational site.

iii) Subjects with proven metal sensitivity.

iv) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc.

v) Women who are pregnant or who intend to become pregnant within 2 years of surgery.

vi) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.

vii) Subjects who have participated in a clinical study with an investigational product in the last 6 month(s).

viii) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation.

ix) Subjects who are currently involved in any injury litigation claims.

x) Subjects who are undergoing corticosteroid treatment.

xi) Subjects with active or recent joint sepsis.

Additional Exclusion Criteria for DePuy ASR™:

i) Subjects with proven significant osteoporosis and poor bone quality.

ii) Subjects with marked atrophy or deformity in the upper femur, skeletal immaturity, or where loss of musculature or neuromuscular disease would render the procedure unjustifiable.

iii) Subjects whose anatomical CCD angle is below 120°.

iv) Subjects who have undergone irradiation of the affected hip.

Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Czech Republic,   Finland,   Germany,   Norway,   Portugal,   Switzerland,   United Kingdom
 
NCT00872547
CT05/18
No
Jack Mantel, Senior Clinical Research Associate, DePuy International Ltd
DePuy International
Not Provided
Not Provided
DePuy International
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP